Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Heterologous AD5-nCOV plus CoronaVac versus homologous CoronaVac vaccination: a randomized phase 4 trial
Jingxin Li, Lihua Hou, Xiling Guo, et al.
Nature Medicine (2022) Vol. 28, Iss. 2, pp. 401-409
Open Access | Times Cited: 140

Showing 1-25 of 140 citing articles:

COVID-19 vaccine development: milestones, lessons and prospects
Maochen Li, Han Wang, Lili Tian, et al.
Signal Transduction and Targeted Therapy (2022) Vol. 7, Iss. 1
Open Access | Times Cited: 342
Current evidence on efficacy of COVID‐19 booster dose vaccination against the Omicron variant: A systematic review
Santenna Chenchula, Padmavathi Karunakaran, Sushil Sharma, et al.
Journal of Medical Virology (2022) Vol. 94, Iss. 7, pp. 2969-2976
Open Access | Times Cited: 301
COVID-19 vaccine update: vaccine effectiveness, SARS-CoV-2 variants, boosters, adverse effects, and immune correlates of protection
Wei-Yu Chi, Yen-Der Li, Hsin‐Che Huang, et al.
Journal of Biomedical Science (2022) Vol. 29, Iss. 1
Open Access | Times Cited: 178
The humoral response and antibodies against SARS-CoV-2 infection
Hai Qi, Bo Liu, Xinquan Wang, et al.
Nature Immunology (2022) Vol. 23, Iss. 7, pp. 1008-1020
Open Access | Times Cited: 151
Safety and immunogenicity of heterologous boost immunisation with an orally administered aerosolised Ad5-nCoV after two-dose priming with an inactivated SARS-CoV-2 vaccine in Chinese adults: a randomised, open-label, single-centre trial
Jingxin Li, Shipo Wu, Xiling Guo, et al.
The Lancet Respiratory Medicine (2022) Vol. 10, Iss. 8, pp. 739-748
Open Access | Times Cited: 124
Viral vectored vaccines: design, development, preventive and therapeutic applications in human diseases
Shen Wang, Bo Liang, Weiqi Wang, et al.
Signal Transduction and Targeted Therapy (2023) Vol. 8, Iss. 1
Open Access | Times Cited: 97
An update on COVID-19: SARS-CoV-2 variants, antiviral drugs, and vaccines
V. Edwin Hillary, Stanislaus Antony Ceasar
Heliyon (2023) Vol. 9, Iss. 3, pp. e13952-e13952
Open Access | Times Cited: 80
Viral Vector Vaccine Development and Application during the COVID-19 Pandemic
Shaofeng Deng, Hui Liang, Chen Pin, et al.
Microorganisms (2022) Vol. 10, Iss. 7, pp. 1450-1450
Open Access | Times Cited: 75
An intranasal combination vaccine induces systemic and mucosal immunity against COVID-19 and influenza
Man Xing, Gaowei Hu, Xiang Wang, et al.
npj Vaccines (2024) Vol. 9, Iss. 1
Open Access | Times Cited: 18
Challenges and developments in universal vaccine design against SARS-CoV-2 variants
Fangxin Zhao, Xiaodong Zai, Zhiling Zhang, et al.
npj Vaccines (2022) Vol. 7, Iss. 1
Open Access | Times Cited: 60
Safety and immunogenicity of aerosolised Ad5-nCoV, intramuscular Ad5-nCoV, or inactivated COVID-19 vaccine CoronaVac given as the second booster following three doses of CoronaVac: a multicentre, open-label, phase 4, randomised trial
Rong Tang, Hui Zheng, Busen Wang, et al.
The Lancet Respiratory Medicine (2023) Vol. 11, Iss. 7, pp. 613-623
Open Access | Times Cited: 36
Safety, immunogenicity and protection of heterologous boost with an aerosolised Ad5-nCoV after two-dose inactivated COVID-19 vaccines in adults: a multicentre, open-label phase 3 trial
Jingxin Li, Lihua Hou, Jin-Bo Gou, et al.
The Lancet Infectious Diseases (2023) Vol. 23, Iss. 10, pp. 1143-1152
Open Access | Times Cited: 34
Emerging and reemerging infectious diseases: global trends and new strategies for their prevention and control
Shen Wang, Wujian Li, Zhenshan Wang, et al.
Signal Transduction and Targeted Therapy (2024) Vol. 9, Iss. 1
Open Access | Times Cited: 10
Comparing reactogenicity of COVID-19 vaccine boosters: a systematic review and meta-analysis
Alberto San Francisco Ramos, Carolina Liu-Sanchez, Tatiana Bovill Rose, et al.
Expert Review of Vaccines (2024) Vol. 23, Iss. 1, pp. 266-282
Open Access | Times Cited: 9
Transformative Approaches in SARS-CoV-2 Management: Vaccines, Therapeutics and Future Direction
Ankita Saha, Shweta Choudhary, Priyanshu Walia, et al.
Virology (2025) Vol. 604, pp. 110394-110394
Closed Access | Times Cited: 1
Interim analysis of SARS-CoV-2 vaccine NVX-CoV2601 as a heterologous booster dose
Pragya D. Yadav, Deepak Y Patil
The Lancet Infectious Diseases (2025)
Closed Access | Times Cited: 1
Comparison of the Effectiveness and Safety of Heterologous Booster Doses with Homologous Booster Doses for SARS-CoV-2 Vaccines: A Systematic Review and Meta-Analysis
Jie Deng, Yirui Ma, Qiao Liu, et al.
International Journal of Environmental Research and Public Health (2022) Vol. 19, Iss. 17, pp. 10752-10752
Open Access | Times Cited: 36
Efficacy, immunogenicity and safety of COVID-19 vaccines in older adults: a systematic review and meta-analysis
Zejun Li, Shouhuan Liu, Fengming Li, et al.
Frontiers in Immunology (2022) Vol. 13
Open Access | Times Cited: 32
Immunogenicity, durability, and safety of an mRNA and three platform-based COVID-19 vaccines as a third dose following two doses of CoronaVac in China: A randomised, double-blinded, placebo-controlled, phase 2 trial
Yuemiao Zhang, Xupu Ma, Guanghong Yan, et al.
EClinicalMedicine (2022) Vol. 54, pp. 101680-101680
Open Access | Times Cited: 30
Safety, immunogenicity, and efficacy of the mRNA vaccine CS-2034 as a heterologous booster versus homologous booster with BBIBP-CorV in adults aged ≥18 years: a randomised, double-blind, phase 2b trial
Jundong Wu, Jingxin Li, Jian Liu, et al.
The Lancet Infectious Diseases (2023) Vol. 23, Iss. 9, pp. 1020-1030
Closed Access | Times Cited: 19
From Immunogen to COVID-19 vaccines: Prospects for the post-pandemic era
Ganggang Miao, Zhiqiang Chen, Hengsong Cao, et al.
Biomedicine & Pharmacotherapy (2023) Vol. 158, pp. 114208-114208
Open Access | Times Cited: 17
Immunogenicity and safety of NVSI-06-07 as a heterologous booster after priming with BBIBP-CorV: a phase 2 trial
Nawal Al Kaabi, Yun Yang, Jing Zhang, et al.
Signal Transduction and Targeted Therapy (2022) Vol. 7, Iss. 1
Open Access | Times Cited: 28
Electrochemical Immunosensors Based on Zinc Oxide Nanorods for Detection of Antibodies Against SARS-CoV-2 Spike Protein in Convalescent and Vaccinated Individuals
Freddy A. Nunez, Ana Cristina Honorato de Castro, Vivian L. de Oliveira, et al.
ACS Biomaterials Science & Engineering (2022) Vol. 9, Iss. 1, pp. 458-473
Closed Access | Times Cited: 27
Six-month follow-up of a booster dose of CoronaVac in two single-centre phase 2 clinical trials
Qianqian Xin, Qianhui Wu, Xinhua Chen, et al.
Nature Communications (2022) Vol. 13, Iss. 1
Open Access | Times Cited: 24
A Heterologous V-01 or Variant-Matched Bivalent V-01D-351 Booster following Primary Series of Inactivated Vaccine Enhances the Neutralizing Capacity against SARS-CoV-2 Delta and Omicron Strains
Zhiren Zhang, Qiaren He, Wei Zhao, et al.
Journal of Clinical Medicine (2022) Vol. 11, Iss. 14, pp. 4164-4164
Open Access | Times Cited: 23
Page 1 - Next Page

Scroll to top